Navigation Links
Dendreon Reports First Quarter 2011 Financial Results
Date:5/2/2011

target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE.  Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. DENDREON CORPORATIONCONSOLI
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon to Host Conference Call on May 2, 2011 to Announce First Quarter 2011 Financial Results
2. Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
3. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
4. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
5. Dendreon to Host Conference Call on March 1st to Announce Fourth Quarter and Year-End Financial Results
6. Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
7. Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
8. Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
9. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
10. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
11. Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015  Adaptive Biotechnologies today announced publication of ... Oncology showing that analysis of circulating tumor ... residual disease (MRD) detection and quantification technology (available ... patients with diffuse large B-cell lymphoma (DLBCL) who ... usually several months before disease can be detected ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 ... (AFM) was selected to receive the prestigious “Best ... Economy Magazine.    Park NX10 is the premium research-grade True ... Z scanner linearity, closed-loop detector noise, and minimized ... SmartSca n, which allows images with a ...
(Date:4/1/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... to announce that Biohaven Pharmaceutical Holding Company Limited ... into an agreement with inVentiv Health for the ... their lead compound (BHV-0223). Biohaven ... clinical stage neuroscience compounds targeting the glutamatergic system. ...
(Date:4/1/2015)... 2015  Among 1,050 U.S. consumers, the majority knows ... percent) and only 36 percent reported being screened for ... findings from a survey released today by  ... developer of solutions that aid in the early detection ... polled 1,050 U.S. consumers on their knowledge of risk ...
Breaking Biology Technology:Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Park Systems Awarded the New Economy Magazine “Best Analytic Instrumentation Company 2014” 2Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4
... and OMX Nordic Exchange: EPCT) today announced that ... be presenting at the IBC conference,on Assays and ... San Diego, CA,on October 17, 2007. Dr. Drewe ... discovery efforts targeting the Myc oncogene pathway,utilizing EpiCept,s ...
... NEW YORK, Oct. 15 Senex Biotechnology, Inc. ... at the 8th International,Conference on Alzheimer,s Disease Drug ... of Senex, described the identification of the first,drug ... amounts of,several proteins involved in Alzheimer,s disease, including: ...
... Therapeutics, Inc.,has named Jeffrey N. Fellows, a biotechnology ... regulatory experience, as Vice President,of Regulatory Affairs. ... PhD, said,"Jeff is a great addition to our ... clinical trials applications, regulatory compliance and,interactions with the ...
Cached Biology Technology:EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 2EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 3EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 4EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 5Senex Biotechnology Announces Presentation of Alzheimer's Disease Drug Discovery Effort 2Senex Biotechnology Announces Presentation of Alzheimer's Disease Drug Discovery Effort 3Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs 2
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... Service and the Southern Group of State Foresters released the ... Tuesday, May 17, which identifies areas forest managers will focus ... According to the report, urbanization, bioenergy use, weather patterns, ... South,s forests between the years 2010 and 2060. About ...
... be nutritional powerhouses, but some types are no match ... "mummy berry" disease. Fortunately, U.S. Department of Agriculture ... in blueberry breeding and cultivation. Geneticist Mark Ehlenfeldt and ... They work for USDA,s Agricultural Research Service (ARS). ...
... have been reviewing the family-group names in several major ... works is to provide a foundation of valid, accepted ... taxa, facilitate decisions on priority, promote long-term stability of ... transition of taxonomy into the digital age. A ...
Cached Biology News:Forest Service unveils first comprehensive forecast on southern forests 2Forest Service unveils first comprehensive forecast on southern forests 3